InMed Reports Third-Quarter 2026 Loss of $2.33 Million
InMed Pharmaceuticals reported discontinued-operations sales of $157,000, down 86% from $1.12 million a year earlier. Net loss was $2.33 million versus $1.73 million, and diluted loss per share was $0.42 versus $0.44.
InMed Pharmaceuticals reported third-quarter 2026 discontinued-operations sales of $157K, down 86% from $1.12M a year earlier, and a net loss of $2.33M compared with a $1.73M loss. Total diluted loss per share was $0.42, versus $0.44 in the prior-year quarter.Financial HighlightsBusiness Highlights…